Economic cost of hemodialysis and peritoneal dialysis under public-private partnership in a public tertiary care centre of Puducherry, India.

IF 1.8 4区医学 Q3 HEALTH CARE SCIENCES & SERVICES

Expert Review of Pharmacoeconomics & Outcomes Research Pub Date : 2024-12-18 DOI:10.1080/14737167.2024.2439515

Vanjavakam Sahithya, Parthibane Sivanantham, Jeyanthi Anandraj, Sreejith Parameswaran, Sitanshu Sekhar Kar

{"title":"Economic cost of hemodialysis and peritoneal dialysis under public-private partnership in a public tertiary care centre of Puducherry, India.","authors":"Vanjavakam Sahithya, Parthibane Sivanantham, Jeyanthi Anandraj, Sreejith Parameswaran, Sitanshu Sekhar Kar","doi":"10.1080/14737167.2024.2439515","DOIUrl":null,"url":null,"abstract":"Background: India faces over 220 000 lakh new kidney failure cases annually, requiring approximately 34 million dialysis sessions, creating a significant economic burden on the healthcare system. This study estimates the costs of providing hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD) under a Public-Private Partnership (PPP) in a tertiary hospital.Methods: Economic health system costs (October 2021-2022) were estimated using a bottom-up approach. Resources consumed were identified, measured, and valued. Capital costs were annualized and discounted at 3%. Sensitivity analysis assessed the impact of variations in input costs.Results: The total annual economic cost for HD (n = 103) under PPP was INR 32 611 618 (USD 393 432), and for CAPD (n = 12) was INR 4 103 781 (USD 49 509). The annual cost per beneficiary for HD and CAPD was INR 316 618 (USD 3820) and INR 341 979 (USD 4126), respectively. Unit cost per HD session was INR 1856 (USD 22) and per CAPD exchange was INR 323 (USD 4).Conclusion: This study provides detailed costs of HD and CAPD services under PPP, offering insights for expanding dialysis services under the Pradhan Mantri National Dialysis Programme and supporting cost-effectiveness analysis for resource allocation.","PeriodicalId":12244,"journal":{"name":"Expert Review of Pharmacoeconomics & Outcomes Research","volume":" ","pages":"1-7"},"PeriodicalIF":1.8000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Pharmacoeconomics & Outcomes Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737167.2024.2439515","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: India faces over 220 000 lakh new kidney failure cases annually, requiring approximately 34 million dialysis sessions, creating a significant economic burden on the healthcare system. This study estimates the costs of providing hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD) under a Public-Private Partnership (PPP) in a tertiary hospital.

Methods: Economic health system costs (October 2021-2022) were estimated using a bottom-up approach. Resources consumed were identified, measured, and valued. Capital costs were annualized and discounted at 3%. Sensitivity analysis assessed the impact of variations in input costs.

Results: The total annual economic cost for HD (n = 103) under PPP was INR 32 611 618 (USD 393 432), and for CAPD (n = 12) was INR 4 103 781 (USD 49 509). The annual cost per beneficiary for HD and CAPD was INR 316 618 (USD 3820) and INR 341 979 (USD 4126), respectively. Unit cost per HD session was INR 1856 (USD 22) and per CAPD exchange was INR 323 (USD 4).

Conclusion: This study provides detailed costs of HD and CAPD services under PPP, offering insights for expanding dialysis services under the Pradhan Mantri National Dialysis Programme and supporting cost-effectiveness analysis for resource allocation.

查看原文本刊更多论文

印度普杜切里公立三级保健中心公私伙伴关系下血液透析和腹膜透析的经济成本。

背景：印度每年面临超过22万新发肾衰竭病例，需要大约3400万次透析，给医疗保健系统造成了重大的经济负担。本研究估算了一家三级医院在公私合作（PPP）模式下提供血液透析（HD）和持续动态腹膜透析（CAPD）的成本。方法：采用自下而上的方法估算经济卫生系统成本（2021-2022年10月）。所消耗的资源被识别、测量和评估。资本成本按年化折现3%。敏感性分析评估了投入成本变化的影响。结果：按购买力平价计算，HD （n = 103）的年总经济成本为32 611 618印度卢比（393 432美元），CAPD （n = 12）的年总经济成本为4 103 781印度卢比（49 509美元）。HD和CAPD的每位受益人的年成本分别为316618印度卢比（3820美元）和34979印度卢比（4126美元）。每次HD会话的单位成本为1856印度卢比（22美元），每次CAPD交换的单位成本为323印度卢比（4美元）。结论：本研究提供了PPP下HD和CAPD服务的详细成本，为在Pradhan Mantri国家透析计划下扩大透析服务提供了见解，并支持资源分配的成本效益分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Pharmacoeconomics & Outcomes Research HEALTH CARE SCIENCES & SERVICES-PHARMACOLOGY & PHARMACY

CiteScore

4.00

自引率

4.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Expert Review of Pharmacoeconomics & Outcomes Research (ISSN 1473-7167) provides expert reviews on cost-benefit and pharmacoeconomic issues relating to the clinical use of drugs and therapeutic approaches. Coverage includes pharmacoeconomics and quality-of-life research, therapeutic outcomes, evidence-based medicine and cost-benefit research. All articles are subject to rigorous peer-review. The journal adopts the unique Expert Review article format, offering a complete overview of current thinking in a key technology area, research or clinical practice, augmented by the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.